KR950032275A - 시클로펩티드 유도체 및 이의 제조방법 - Google Patents

시클로펩티드 유도체 및 이의 제조방법 Download PDF

Info

Publication number
KR950032275A
KR950032275A KR1019950010234A KR19950010234A KR950032275A KR 950032275 A KR950032275 A KR 950032275A KR 1019950010234 A KR1019950010234 A KR 1019950010234A KR 19950010234 A KR19950010234 A KR 19950010234A KR 950032275 A KR950032275 A KR 950032275A
Authority
KR
South Korea
Prior art keywords
arg
asp
gly
formula
cyclo
Prior art date
Application number
KR1019950010234A
Other languages
English (en)
Other versions
KR100360831B1 (ko
Inventor
용시크 알프레트
횔제만 귄터
구드만 시몬
케슬러 호르스트
하우브너 롤란트
베르무쓰 요헨
Original Assignee
위르겐 호이만·라인하르트 쉬틀러
메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위르겐 호이만·라인하르트 쉬틀러, 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁 filed Critical 위르겐 호이만·라인하르트 쉬틀러
Publication of KR950032275A publication Critical patent/KR950032275A/ko
Application granted granted Critical
Publication of KR100360831B1 publication Critical patent/KR100360831B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

본 발명은 다음 일반식(I)의 새로운 시클로펩티드 및 이의 염을 제공한다.
시클로-(Arg-A-Asp-R1-R2)
(단, 상기 식에서, A는 Gly 또는 Ala이고, R1은 2-카르복시-8-아미노-4-티아피페롤리딘-9-온(Btd), o-아미노메틸-o'-카르복시페닐(Biph), 2-아미노메틸-5-카르복시네틸티오펜(Act) 또는 6-아미노헥산산 라디칼(Aha) 또는 2-(1,7-디아자스프로-[4,4]노난-7-일)-4-메틸펜탄산(S,S)스피로-Pro-Leu) 또는 2-(3-아미노-1-피롤리드-2-온일)-4-메틸-펜탄산라디칼((S)Gly[ANC-2]-Leu 또는 (R)Gly[ANC-2]-Leu 라디칼)이고, 각 경우에 라디칼은 펩티드 결합을 통해 결합되고, 그리고 R2는 존재하지 않거나 있는 경우에는 Val이다.)
본 발명의 화합물은 인테그린 억제제로서 작용하고 순환계 질환의 예방과 치료 및 종양 치료에 사용할 수 있으며, 항균성 항바이러스성 활성 화합물로서 사용할 수 있다.

Description

시클로펩티드 유도체 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(I)의 시클로펩티드 및 이의 생리학적으로 허용하는 염:
    시클로-(Arg-A-Asp-R1-R2) (I)
    (단, 상기 식에서, A는 Gly 또는 Ala이고, R1은 2-카르복시-8-아미노-4-티아피페롤리딘-9-온(Btd), o-아미노메틸-o'-카르복시페닐(Biph), 2-아미노메틸-5-카르복시네틸티오펜(Act) 또는 6-아미노헥산산 라디칼(Aha) 또는 2-(1,7-디아자스프로-[4,4]노난-7-일)-4-메틸펜탄산(S,S)스피로-Pro-Leu) 또는 2-(3-아미노-1-피롤리드-2-온일)-4-메틸-펜탄산라디칼((S)Gly[ANC-2]-Leu 또는 (R)Gly[ANC-2]-Leu 라디칼)이고, 각 경우에 라디칼은 펩티드 결합을 통해 결합되고, 그리고 R2는 존재하지 않거나 있는 경우에는 Val이다.)
  2. 제1항에 있어서, 일반식(I)의 화합물이 하기 (a)~(h)중의 어느 하나인 것을 특징으로 하는 시클로펩티드.
    (a) 시클로-(Arg-Gly-Asp-(S)Gly[ANC-2]-Leu); (b) 시클로-(Arg-(R)Gly[ANC-2]-Leu); (c) 시클로-(Arg-Gly-Asp-(S,S)스피로Pro-Leu); (d) 시클로-(Arg-Gly-Asp-Act); (e) 시클로-(Arg-Gly-Asp-Btd); (f) 시클로-(Arg-Gly-Asp-Aha); (g) 시클로-(Arg-Gly-Asp-Btd-Val); (h) 시클로-(Arg-DAla-Asp-Btd-Val)
  3. 제1항에 따른 일반식(I)의 화합물이 거울상 이성질체 또는 부분입체 이성질체.
  4. 제1항에 따른 일반식(I)의 화합물 또는 이의 염증 하나를 제조하는 방법에 있어서,이의 작용성 유도체중 하나로부터 가용매분해제 또는 가수소분해제로 처리하여 유리시키거나, 또는 하기 일반식(II)의 펩티드 또는 이러한 펩티드의 기능성 유도체를 환화제로 처리하거나 및/또는 생성된 일반식(I)의 염기성 또는 산성 화합물을 산 또는 염기로 처리함으로써 이의 염증의 하나로 전환시키는 것을 특징으로 하는 제조방법.
    H-Z-OH (Ⅱ)
    (단, 상기 식에서, Z는 -Arg-A-Asp-R1-R2-, -A-Asp-R1-R2-Arg-, -Asp-R1-R2-Arg-A-, -R1-R2-Arg-A-Asp- 또는 -R2-Arg-A-Asp-R1-이다.)
  5. 제1항에 따른 일반식(I)의 화합물 및/또는 이의 생리학적으로 허용되는 염증의 하나를 1종 이상의 고체, 액체 또는 반고체 부형제 또는 보조제와 함께 적합한 투여형태로 전환시킴을 특징으로 하는 약제학적 제형의 제조방법.
  6. 제1항에 따른 일반식(I)의 화합물 1종 이상 및/또는 이의 생리학적으로 허용되는 염증의 하나를 함유하는 것을 특징으로 하는 약제학적 제형.
  7. 제1항에 따른 일반식(I)의 화합물 또는 이의 생리학적으로 허용되는 염을 질병의 치료를 위한 약물제조에 사용하는 용도.
  8. 제1항에 따른 일반식(I)의 화합물 또는 이의 생리학적으로 허용되는 염을 질병의 치료에 사용하는 용도.
  9. 제1항에 따른 일반식(I)의 화합물을 친화성 컬럼 크로마토그래피용 고정상 리간드의 제조에 사용하는 용도.
  10. 제1항에 따른 일반식(I)의 화합물을 친화성 크로마토그라피에 의한 인테그린의 정제에 사용하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950010234A 1994-04-30 1995-04-28 시클로펩티드유도체및이의제조방법 KR100360831B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4415310.4 1994-04-30
DE4415310A DE4415310A1 (de) 1994-04-30 1994-04-30 Cyclopeptide

Publications (2)

Publication Number Publication Date
KR950032275A true KR950032275A (ko) 1995-12-20
KR100360831B1 KR100360831B1 (ko) 2003-01-24

Family

ID=6516993

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950010234A KR100360831B1 (ko) 1994-04-30 1995-04-28 시클로펩티드유도체및이의제조방법

Country Status (21)

Country Link
US (1) US5693612A (ko)
EP (1) EP0683173B1 (ko)
JP (1) JP3711154B2 (ko)
KR (1) KR100360831B1 (ko)
CN (1) CN1161374C (ko)
AT (1) ATE183199T1 (ko)
AU (1) AU697614B2 (ko)
CA (1) CA2148194C (ko)
CZ (1) CZ286705B6 (ko)
DE (2) DE4415310A1 (ko)
DK (1) DK0683173T3 (ko)
ES (1) ES2137394T3 (ko)
GR (1) GR3031696T3 (ko)
HU (1) HU216795B (ko)
NO (1) NO311892B1 (ko)
PL (1) PL181272B1 (ko)
RU (1) RU2151776C1 (ko)
SK (1) SK281843B6 (ko)
TW (1) TW354790B (ko)
UA (1) UA46699C2 (ko)
ZA (1) ZA953467B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244622B2 (en) * 1996-04-03 2007-07-17 Applera Corporation Device and method for multiple analyte detection
DE19736772A1 (de) * 1997-08-23 1999-02-25 Merck Patent Gmbh Cyclopeptidderivate
CN1346282A (zh) 1998-12-23 2002-04-24 G.D.西尔公司 在肿瘤的治疗中使用环加氧酶－2－抑制剂与一种或多种抗肿瘤剂作为联合治疗的方法
CN1507354A (zh) * 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1499352A4 (en) * 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
CA2514653A1 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
CN100429223C (zh) * 2004-02-06 2008-10-29 南京工业大学 环(d-苯丙-d-组)二肽的制备方法
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
AU2005249586B2 (en) 2004-06-04 2010-12-23 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases
WO2006052391A2 (en) * 2004-10-14 2006-05-18 Rigel Pharmaceuticals, Inc. Heterocyclic inhibitors of ires-mediated translation and methods of use thereof
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
ES2357800T3 (es) * 2004-10-30 2011-04-29 Universidad Del Pais Vasco-Euskal Herriko Unibersitatea Ciclopéptidos rgd beta-lactámicos que contienen giros gamma.
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA3177366A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
DK2408802T3 (en) * 2009-03-16 2017-08-28 Governing Council Univ Toronto CYCLIC AMINO ACID MOLECULES AND PROCEDURES FOR PREPARING IT
US10562936B2 (en) * 2015-09-18 2020-02-18 Technische Universitat Munchen Ligands for integrin αvβ6, synthesis and uses thereof
CN109071602B (zh) 2015-11-11 2022-09-13 西兰制药公司 靶向α4β7整联蛋白的环肽
DK3538542T3 (da) 2016-11-11 2021-10-11 Zealand Pharma As Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
AU2018266248B2 (en) 2017-05-10 2022-01-27 Zealand Pharma A/S Homodetic cyclic peptides targeting a4β7 integrin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472305A (en) * 1983-05-17 1984-09-18 Sterling Drug Inc. Hexapeptide amides
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1992017492A1 (en) * 1991-04-05 1992-10-15 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?
IL103252A (en) * 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UA43823C2 (uk) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren

Also Published As

Publication number Publication date
PL181272B1 (pl) 2001-07-31
DK0683173T3 (da) 2000-03-13
US5693612A (en) 1997-12-02
HU216795B (hu) 1999-08-30
CN1161374C (zh) 2004-08-11
DE59506568D1 (de) 1999-09-16
ATE183199T1 (de) 1999-08-15
CA2148194C (en) 2007-04-10
HU9501253D0 (en) 1995-06-28
EP0683173A1 (de) 1995-11-22
SK55895A3 (en) 1995-12-06
JP3711154B2 (ja) 2005-10-26
AU697614B2 (en) 1998-10-15
NO951645L (no) 1995-10-31
AU1772495A (en) 1995-11-09
NO951645D0 (no) 1995-04-28
GR3031696T3 (en) 2000-02-29
CZ107395A3 (en) 1995-11-15
RU95106821A (ru) 1997-01-10
CA2148194A1 (en) 1995-10-31
CZ286705B6 (en) 2000-06-14
UA46699C2 (uk) 2002-06-17
PL308420A1 (en) 1995-11-13
TW354790B (en) 1999-03-21
NO311892B1 (no) 2002-02-11
DE4415310A1 (de) 1995-11-02
ES2137394T3 (es) 1999-12-16
KR100360831B1 (ko) 2003-01-24
HUT75057A (en) 1997-03-28
SK281843B6 (sk) 2001-08-06
ZA953467B (en) 1996-01-17
EP0683173B1 (de) 1999-08-11
CN1116628A (zh) 1996-02-14
JPH07304795A (ja) 1995-11-21
RU2151776C1 (ru) 2000-06-27

Similar Documents

Publication Publication Date Title
KR950032275A (ko) 시클로펩티드 유도체 및 이의 제조방법
JP4192114B2 (ja) 環式付着阻害剤
EP0632053B1 (de) Cyclische Adhäsionsinhibitoren
AU669922B2 (en) Thrombin receptor antagonists
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
EA199900499A1 (ru) Фармацевтическая композиция, включающая соединение, обладающее анти-xa активностью, и соединение антагонист агрегации тромбоцитов
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
HU205008B (en) Process for producing pharmaceutical compositions suitable for treating cardial and vascular hypertrophy and hyperplasia
JPH03120297A (ja) 抗凝固ペプチド
RU2000101296A (ru) Циклические азапептиды с ангиогенным действием
CA2465667A1 (en) New peptides - analogs of human growth hormone-releasing hormone
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
RU99115767A (ru) Производные циклопептидов
CA2465245A1 (en) Biologically active peptides and their use for repairing injured nerves
DE69420574D1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
KR940011479A (ko) 시클로 펩티드
RU2002124494A (ru) Ингибиторы интегрина αvβ6
MX9601424A (es) Indenoilguanidinas sustituidas antiarritmicas y cardioprotectoras.
RU93045437A (ru) Вещество, обладающее активностью паратиреоидного гипертензивного фактора, и способ повышения артериального давления
MX9601659A (es) Antagonistas del receptor de adhesion, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades.
RU93049414A (ru) Производные бенз(е)индена
RU2002102252A (ru) Производные циклических пептидов как ингибиторы интегрина αvβ6

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
LAPS Lapse due to unpaid annual fee